Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma?  by Koenig, Steven M. et al.
ARTICLE IN PRESS
Respiratory Medicine (2008) 102, 665–6730954-6111/$ - see fro
doi:10.1016/j.rmed.
Abbreviations: AM
hyperresponsiveness
ﬂuticasone propiona
ﬂuticasone propiona
corticosteroids; ITT,
decrease in FEV1 of
$These data were
3–7, 2006, and the E
Corresponding au
E-mail address: sDoes measuring BHR add to guideline derived clinical
measures in determining treatment for patients with
persistent asthma?$
Steven M. Koeniga,, John J. Murrayb, James Wolfec, Leslie Andersend,
Steve Yanceyd, Barbara Prillamand, John Stauffere, Paul DorinskydaDivision of Pulmonary Medicine and Critical Care, University of Virginia, Hospital Drive, Private Clinics #6590,
Charlottesville, VA 22908, USA
bDepartment of Medicine and Biomedical Sciences, Meharry Medical College, 1005 Dr. D.B. Todd Jr. Blvd., Nashville,
TN 37028, USA
cAllergy and Asthma Associates, 393 Blossom Hill Road, San Jose, CA, USA
dGlaxoSmithKline, 5 Moore Dr., Research Triangle Park, NC 27709, USA
eCV Therapeutics, 3172 Porter Drive, Palo Alto, CA 94304, USA
Received 29 June 2007; accepted 21 December 2007
Available online 6 March 2008KEYWORDS
Asthma;
Fluticasone
propionate;
Salmeterol;
Bronchial
hyperresponsiveness;
Methacholine;
Long-acting
beta-agonistsnt matter & 2008
2007.12.023
P, adenosine mo
; BUD, budesonide
te utilizing a bron
te/salmeterol; FSC
intent-to-treat; LA
20% from baseline
presented in part
uropean Respirato
thor. Tel.: +1 434
mk4q@virginia.edSummary
Rationale: Little is known about the use of biomarkers in guiding treatment decisions in
routine asthma management. The objective of this study was to determine whether adding
a LABA to an ICS would control bronchial hyperresponsiveness (BHR) at an overall lower
dose of ICS when titration of medication was based upon the assessment of routine clinical
measures with or without the measurement of BHR.
Methods: After a 2-week run-in period, subjects (X12 years) were randomized to one of
three treatment groups. Two groups followed a BHR treatment strategy (based on clinical
parameters [lung function, asthma symptoms, and bronchodilator use] and BHR) and were
treated with either ﬂuticasone propionate/salmeterol (FSCBHR group) or ﬂuticasone
propionate (FPBHR group) (n ¼ 156 each). The third group followed a clinical treatmentElsevier Ltd. All rights reserved.
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chial hyperresponsiveness strategy; FPREF, ﬂuticasone propionate utilizing a reference strategy; FSC,
BHR, ﬂuticasone propionate/salmeterol utilizing a bronchial hyperresponsiveness strategy; ICS, inhaled
BA, long-acting beta agonist; PC20, provocative concentration of methacholine necessary to produce a
; PEF, peak expiratory ﬂow; TAA, triamcinolone acetonide.
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S.M. Koenig et al.666algorithm (based on clinical parameters alone) and were treated with ﬂuticasone
propionate (FPREF group; n ¼ 154). All treatments were administered via Diskuss.
Treatment doses were adjusted as needed every 8 weeks for 40 weeks according to the
subject’s derived severity class, which was based on clinical measures of asthma control
with or without BHR.
Results: The mean total daily inhaled corticosteroids (ICS) dose during the double-blind
treatment period was lower, although not statistically signiﬁcant, in the FSCBHR group
compared with the FPBHR group (a difference of 42.9mcg; p ¼ 0.07). Compared with the
FPREF group, the mean total daily ICS dose was higher in the FSCBHR group (a difference of
85.2mcg) and was signiﬁcantly higher in the FPBHR group (a difference of 131.2mcg,
p ¼ 0.037).
Conclusion: This study demonstrated that for most subjects, control of BHR was
maintained when treatment was directed toward control of clinical parameters. In
addition, there was a trend towards control of BHR and clinical measures at a lower dose of
ICS when used concurrently with salmeterol.
& 2008 Elsevier Ltd. All rights reserved.Introduction
Asthma is a chronic disease of the airways characterized by
inﬂammation, bronchoconstriction, and bronchial hyperre-
sponsiveness (BHR).1 Inhaled corticosteroids (ICS) are the
gold standard in anti-inﬂammatory therapy since they
are proven to improve asthma symptoms and lung function,
and reduce BHR, inﬂammatory cells and mediators asso-
ciated with asthma.2 However, treatment with ICS alone
does not adequately control clinical symptoms of asthma
in many patients, and in such instances guidelines recom-
mend the addition of controller medications such as
inhaled long-acting beta2-agonists (LABA). Treatment with
ICS plus LABA improves the clinical status of asthma by
attenuating airway inﬂammation and bronchoconstric-
tion.3–11 BHR is a predominant feature of asthma and is
present in patients whose asthma may be active or in
remission.12 A number of studies suggest a positive correla-
tion between increased asthma morbidity, exacerbations,
airway inﬂammation and BHR.13–15 Therefore, increased
BHR may indicate the presence of under-treated airway
inﬂammation and thus be a useful therapeutic target in
asthma.
The clinician must often choose an asthma treatment
management plan based solely on clinical presentation.
However, lack of information about the degree of airway
inﬂammation may lead to under-treatment with anti-
inﬂammatory therapy, which may be associated with long-
term progressive worsening of the disease.16 Markers of
inﬂammation, such as sputum eosinophils, BHR and exhaled
nitric oxide (eNO), have been utilized in clinical trials and
provide insight into the asthmatic inﬂammatory process.15,17
Some studies suggest that low-dose ICS alone may ade-
quately control clinical parameters, lung function and
bronchial hyperreactivity (BHR)18 while other studies sug-
gest that higher doses of ICS are required to do the
same.15,17,19 The objective of this study was to determine
whether adding a LABA to an ICS would control BHR at an
overall lower dose of ICS when titration of medication was
based upon the assessment of routine clinical measures with
or without the measurement of BHR.Methods
Patient selection
Male and female patients, 12 years of age and older, were
eligible to participate in the study if they had asthma for at
least 3 months and had been treated during the previous
month with short-acting beta2-agonists, anticholinergics, or
ICS (p250mcg daily of ﬂuticasone propionate (FP) or
equivalent). At the screening visit, all patients were
required to have a forced expiratory volume in 1 s (FEV1)
between 60% and 95% of predicted normal (based on Crapo
standards for patients 18 years and older20 or Polgar and
Promadhat standards21 for patients 12–17 years, race-
adjusted for African Americans).22 They were also required
to have either historical documentation of reversible
airways disease within the last 24 months or an increase in
FEV1 of at least 12% within 30min of inhalation of 2 puffs
(180mcg) of albuterol. At Visit 2, patients had to demon-
strate a PC20 of o8mg/mL of methacholine.
Exclusion criteria included the following: pregnancy, life-
threatening asthma, hospitalization attributable to asthma
within the last 6 months, current smoker or a410 pack-year
history of smoking, a recent (within 2 weeks) upper or lower
respiratory tract infection, or signiﬁcant concurrent dis-
eases. Medications that could confound the evaluation of
the study treatments or treatment strategies were prohib-
ited before and throughout the study, including inhaled (up
to 250mcg FP allowed prior to randomization), oral, or
parenteral corticosteroids (with the exception of protocol
deﬁned use of oral corticosteroids following second con-
secutive assignment to the highest dose of FP), theophylline
or other bronchodilators, leukotriene modiﬁers, anticholi-
nergics, cromolyn, and nedocromil.Study design and intervention
This randomized, multicenter, double-blind, parallel group
40-week study (SAM40086) was conducted at 50 sites in the
US, three sites in Latin American, and two sites in Latvia.
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tion testing, and other pre-study procedures at the screen-
ing visit (Visit 1).
Eligible patients entered a 2-week run-in period during
which they continued their allowed short-acting beta2-
agonist, anticholinergic, or inhaled corticosteroid treat-
ment. All inhaled short-acting beta2-agonists were replaced
with albuterol (Ventolins HFA inhalation aerosol, Glaxo-
SmithKline, Research Triangle Park, NC) for the duration of
the study. In addition to providing the baseline for efﬁcacy
and safety parameters, this period served to evaluate the
patient’s eligibility for randomization, compliance with
study procedures, and asthma status.
Patients who met all eligibility criteria were randomly
assigned to one of the following treatment arms at Visit 2:
ﬂuticasone propionate/salmeterol DISKUSs (FSC) BID utiliz-
ing the BHR strategy (FSCBHR), FP DISKUS utilizing the BHR
strategy (FPBHR), or FP DISKUS utilizing the reference
strategy (FPREF). All double-blind study drugs were supplied
in identical DISKUS devices to blind the treatment. In each
treatment strategy the starting dose of treatment at
randomization and adjustments to the dose, as needed, at
each 8-week visit for a total of 40 weeks of treatment were
made based on the patient’s asthma Severity Class (Table 1).
The Severity Class was derived by a computerized algorithm
based on clinical measures of asthma control over the 14
days prior to a visit and PC20 on the day of the visit. The
clinical measures of asthma control included asthma
symptoms (rated on a four-point scale with 0 equal to no
symptoms and 3 equal to severe symptoms), bronchodilator
use, and mean PEF variability from daily diary records, and
clinic lung function. Additionally, BHR was also assessed in
all three groups (FSCBHR, FPBHR and FPREF groups).
At each visit, a patient’s Severity Class was determined to
be one of four categories (Table 1) based on the highest level
achieved for any of the clinical measures or BHR. BHR was
not considered in determining Severity Class for patients in
the FPREF group.
Treatment for 8 weeks after each visit was based upon the
Severity Class: Severity Class 1—no requirement for
corticosteroid (placebo); Severity Class 2—FSC 100/50mcg
BID or FP 100mcg BID; Severity Class 3—FSC 250/50mcg BID
or FP 250mcg BID; Severity Class 4—FSC 500/50mcg BID or
FP 500mcg BID. However a patient’s treatment could not be
reduced by more than one step even if they had a two step
or greater improvement in their Severity Class on consecu-
tive visits. If the patient remained in Severity Class 4 for two
consecutive visits (a total of 16 weeks), an oral prednisone
burst of 1mg/kg per day for 4 days followed by half thatTable 1 Severity Class markers.
Severity
Class
Composite symptom
score (0–3 scale)
Mean daily albuterol
use (puffs)
4 3 X6
3 2 4–5.99
2 1 2–3.99
1 0 o2
PEF variability was calculated for each of the 14 days prior to a visi
PEF% variability results from the 14 days preceding each visit were adose for 3 days was added to the inhaled study medication at
the second visit. An exacerbation was deﬁned as worsening
asthma for which treatment with medication other than the
double-blind study drugs or study-provided albuterol was
necessary, and was treated with the same dosing regimen
for prednisone as above.
At each visit, treatment compliance was assessed by
recording the number of doses remaining on the counter for
the DISKUS.
Clinic measurements
FEV1 was performed at each visit and measured using a
standardized KoKo spirometer (Quantum Ferraris Group,
Louisville, CO). BHR was measured through the 5-breath
procedure methacholine challenge test23 and was expressed
as PC20 for FEV1. All FEV1 measurements were performed
prior to the subject receiving their morning dose of study
drug at clinic visits. Methacholine in doubling concentrations
(0.031–16mg/mL) was delivered from a DeVilbiss 646
nebulizer (DeVilbiss, Somerset, PA) connected to a KoKo
DigiDoser (Quantum Ferraris Group, Louisville, CO). The
challenge test was discontinued if FEV1 fell by more than
20% from its baseline value, if the patient felt uncomfor-
table, or if the highest concentration of methacholine had
been given. Spirometric and BHR results were transmitted
electronically to a central data collection site (Quantum
Ferraris Group, Louisville, CO).
Statistical analyses
The estimated mean daily dose of ICS for each group was
derived from estimates of the overall expected proportions
of the treatment period subjects would spend in each
Severity Class (i.e., on each ICS dose). For the FSCBHR group,
the expected proportion of time by ICS dose was as follows:
placebo: 2%, 100mcg BID: 53%, 250mcg BID: 43%, and
500mcg BID: 2%; and for the FPBHR group: placebo: 0%,
100mcg BID 7%, 250mcg BID: 85%, and 500mcg BID: 8%.
Based on these estimates, over the treatment period of 40
weeks, the expected mean daily dose for the FSCBHR group
was 170.5mcg BID and for the FPBHR group was 259.5mcg BID
(a difference of 89mcg). Based on a two-group t-test with a
signiﬁcance level of 0.05, a sample size of 43 subjects in
each group would have 90% power to detect a difference in
mean daily ICS dose of 89mcg (the difference between the
FSCBHR mean of 170.5mcg and the FPBHR mean of
259.5mcg). In the absence of data to determine an accurateMean PEF
variability (%)
FEV1 (% of
predicted)
PC20 (mg/mL)
450 o50 o0.25
31–50 50–69 0.25–1.0
20–30 70–90 1.1–4.0
o20 490 44.0
t as (morning PEFevening PEF)/(evening PEF) 100. The daily
veraged to determine the mean PEF% variability.
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inhaled corticosteroid, the sample size estimate was based
on a standard deviation equal to 125, which corresponds to
one-fourth the range of possible doses (0–500mcg). How-
ever, it was anticipated that the variability of these results
could be greater than the rough estimate of 125mcg.
Therefore, the sample size for this study was increased to
100 subjects per group.
All efﬁcacy and safety analyses were based on the intent-to-
treat (ITT) population, which comprised all randomized
patients. The analyses of the ITT population included all data
available from these subjects, except in the case of the primary
efﬁcacy measure, the average daily ICS dose comparing
FSCBHR with FPBHR, which required at least two on-treatment
clinic visits in order to calculate a weighted average ICS dose.
The primary efﬁcacy measure, the average daily ICS dose
(averaged over the entire treatment period) comparing
FSCBHR with FPBHR, was calculated as the area under the
dose-by-time curve, and analyzed using van Elteren tests
stratiﬁed by baseline Severity Class. The primary efﬁcacy
measure was evaluated at a signiﬁcance level of 0.05. All
statistical hypotheses were tested using two-tailed tests.
Median treatment differences and their corresponding 95%
conﬁdence intervals were derived using Hodges–Lehmann
estimation methods. Secondary efﬁcacy measures and re-
spective related measures (in parentheses) were as follows:
morning PEF (evening PEF); morning pre-dose FEV1; percen-
tage of symptom-free days (number of nighttime awakenings
and symptom scores); and daily albuterol use (percentage of
albuterol-free days). Secondary and related measures were
analyzed by 28-day intervals and at endpoint (the average ofPatients Rand
n=466
Discontinued n=47 (30%) 
Adverse Event:  3 (2) 
Consent Withdrawn: 8 (5) 
Lost to Follow-up: 8 (5) 
Protocol Violation: 8 (5) 
Worsening asthma: 2 (1) 
Other: 18 (12)* 
FSC BHR
n=156
Completed 
n=109 (70%) 
Discontinued n=5
Adverse Even
Consent With
Lost to Follow
Protocol Viola
Worsening ast
Other: 21 (13)
FP BHR
n=156
Complete
n= 105 (67
Figure 1 Patient ﬂow diagram. *The ‘‘Other’’ reasons for subject
from area, dissatisfaction with medication, investigator discretion,the data recorded over the last 7 days of study participation)
in terms of change from baseline, using analysis of covariance
models that included baseline (the average of the data
recorded over the last 7 days prior to randomization) as a
covariate and terms for treatment and baseline severity class.
Safety was assessed in terms of the frequency of clinical
adverse events and asthma exacerbations by group.
For a given pairwise treatment comparison, secondary
and related efﬁcacy measures were assessed for statistical
signiﬁcance only if the primary measure was deemed to be
statistically signiﬁcant. The set of secondary efﬁcacy
measures was subject to the following disclosure-of-results
scheme. Reporting the results of one measure in this set of
secondary measures required reporting results of all other
measures in the set, regardless of the statistical signiﬁcance
associated with the tests of the measures. Conversely,
choosing not to report any one measure in the set required
that none of the other measures in the set be reported. Each
secondary efﬁcacy measure was evaluated at a signiﬁcance
level of 0.05. In addition, no related efﬁcacy measure was
assessed for statistical signiﬁcance unless its parent measure
(i.e., the secondary measure to which it is related) was
deemed to be statistically signiﬁcant.Results
A total of 466 subjects were randomly assigned to one of the
three study drug treatment groups (FSC groups: FSCBHR,
FPBHR, and FPREF). The initial dose of ICS at randomization
was determined by the BHR (clinical parameter plus BHR) oromized 
Discontinued n=47 (31%) 
Adverse Event:  6 (4) 
Consent Withdrawn: 10 (6) 
Lost to Follow-up: 4 (3) 
Protocol Violation: 12 (8) 
Worsening asthma: 4 (3) 
Other: 11 (7)* 
FP Ref 
n=154
Completed 
n= 107 (69%) 
1 (33%) 
t:  7 (4) 
drawn: 6 (4) 
-up: 7 (8) 
tion: 7 (4) 
hma: 3 (2) 
* 
 
d 
%) 
withdrawal included sponsor discretion, non-compliance, move
positive pregnancy test, and inconsistent PFT efforts.
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Table 2 Patient background characteristics.
FSCBHR,
N ¼ 156
FPBHR,
N ¼ 156
FPREF,
N ¼ 154
Male/female, % 38/62 36/64 49/51
Mean age, years
(range)
34.8 (12–81) 34.8 (12–81) 33.2 (12–72)
Ethnic origin, no. (%)
White 124 (79) 120 (77) 124 (81)
Black 18 (12) 24 (15) 16 (10)
Other 14 (9) 12 (8) 14 (9)
Mean FEV1 at baseline (S.D.)
% Predicted 77 (9.6) 79 (9.2) 79 (9.6)
% Reversibility 19 (7.9) 20 (11.0) 20 (9.7)
Table 3 Efﬁcacy assessments.
FSCBHR, N ¼
Primary efﬁcacy
Inhaled corticosteroid daily dose (mcg)
Median (minimum–maximum) 368.7 (111.
FSCBHR vs.
Mean treatment difference (mcg) 42.9
95% conﬁdence interval 89.6, 2.0
p-value 0.070
Secondary and relatedy efﬁcacy
AM PEF (L/min)
Baseline least squares mean (S.E.) 401 (13.5)
Least squares mean change at endpoint (S.E.) 31.3 (9.1)
PM PEF (L/min)y
Baseline least squares mean (S.E.) 416 (14.2)
Least squares mean change at endpoint (S.E.) 26.8 (8.7)
Pre-dose FEV1 (L)

Baseline least squares mean (S.E.) 2.75 (0.08)
Least squares mean change at endpoint (S.E.) 0.14 (0.05)
% Symptom-free days
Baseline least squares mean (S.E.) 45.0 (4.07)
Least squares mean change at endpoint (S.E.) 19.9 (5.48)
Nighttime awakeningsy
Baseline least squares mean (S.E.) 0.3 (0.08)
Least squares mean change at endpoint (S.E.) 0.2 (0.04
24-h Asthma symptom scoresy
Baseline least squares mean (S.E.) 0.7 (0.07)
Least squares mean change at endpoint (S.E.) 0.3 (0.08
24-h Albuterol use (puffs/24 h)
Baseline least squares mean (S.E.) 1.6 (0.24)
Least squares mean change at endpoint (S.E.) 1.2 (0.18
% Albuterol-free daysy
Baseline least squares mean (S.E.) 54.2 (4.54)
Least squares mean change at endpoint (S.E.) 30.4 (5.03)
Secondary efﬁcacy measures.
yRelated efﬁcacy measures (related to preceding secondary measu
BHR plus clinical measures in determining asthma therapy 669REF strategy (clinical parameters alone). A subject ﬂow
diagram is presented in Figure 1.
Randomization resulted in comparable treatment groups
at baseline with respect to patient demographics and
pulmonary function (Table 2).Efﬁcacy assessments
The results of the efﬁcacy assessments are shown in Table 3.
For the primary endpoint the mean total daily ICS dose taken
during the double-blind treatment period was lower in the
FSCBHR group compared with the FPBHR group (a difference
of 42.9mcg; although the difference was not statistically
signiﬁcant, p ¼ 0.07) (Table 3). Compared with the FPREF
group, the mean total daily ICS dose was higher in the FSCBHR
group (a difference of 85.2mcg) and was signiﬁcantly higher156 FPBHR, N ¼ 156 FPREF, N ¼ 154
6–1000.0) 414.3 (80.1–1008.9) 254.0 (18.6–1000.0)
FPBHR FSCBHR vs. FPREF FPBHR vs. FPREF
85.2 131.2
49.8, 125.4 83.2, 178.5
0.554 0.037
409 (13.4) 407 (13.0)
16.9 (9.0) 25.5 (8.9)
423 (14.2) 427 (13.8)
16.4 (8.7) 22.4 (8.6)
2.79 (0.08) 2.80 (0.08)
0.06 (0.05) 0.11 (0.05)
48.0 (4.07) 37.6 (3.95)
13.0 (5.48) 18.1 (5.31)
0.3 (0.08) 0.3 (0.08)
) 0.2 (0.04) 0.1 (0.04)
0.7 (0.07) 0.9 (0.07)
) 0.2 (0.08) 0.3 (0.08)
1.2 (0.24) 2.2 (0.24)
) 0.8 (0.18) 0.7 (0.17)
53.4 (4.54) 45.6 (4.40)
21.2 (5.01) 16.8 (4.87)
re).
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Table 4 Baseline and mean change from baseline in methacholine PC20 (mg/mL).
FSCBHR, N ¼ 156 FPBHR, N ¼ 156 FPREF, N ¼ 154
Baseline geometric mean (S.E.) 0.50 (1.25) 0.48 (1.25) 0.37 (1.26)
Week 8 mean change (S.E.) 2.01 (0.46) 1.60 (0.26) 1.45 (0.27)
Week 16 mean change (S.E.) 2.53 (0.41) 1.56 (0.28) 1.72 (0.38)
Week 24 mean change (S.E.) 2.45 (0.44) 1.56 (0.17) 1.75 (0.51)
Week 32 mean change (S.E.) 2.06 (0.37) 1.52 (0.18) 1.75 (0.35)
Week 40 mean change (S.E.) 1.86 (0.48) 1.75 (0.19) 1.98 (0.59)
S.M. Koenig et al.670in the FPBHR group (a difference of 131.2mcg, p ¼ 0.037).
There were no statistically signiﬁcant differences between
pairs of treatment groups for any secondary or related
efﬁcacy measures. During the treatment period, 5, 15, and 3
subjects remained at Severity Class 4 for two consecutive
visits for the FSCBHR group, FPBHR group, and FPREF group,
respectively. Treatment compliance was high for all three
treatment groups (96%, 94%, and 96%, respectively).
PC20 to methacholine
There were no differences in PC20 between treatments at
baseline and any 8-week clinic visit over the 40-week
treatment period. Compared with the other treatment
groups, the concentration of methacholine relative to
baseline required to effect a 20% fall in FEV1 at each visit
(except at Week 40, compared with the FPREF group) was
numerically greater in the FSCBHR group, indicating greater
improvements in airway hyperresponsiveness (Table 4).
Safety
All treatments were well tolerated during the 40-week study
period. There were no non-fatal serious adverse events in
any treatment group that were considered to be drug-
related. One subject in the FPBHR treatment group died due
to convulsions and cardiac arrest following deep vein
thrombosis. The death was not considered by the investi-
gator to be related to study medication. The incidence of
common and pharmacologically predictable adverse events
was similar, with 81% of patients reporting one or more
adverse events. Infections were the most frequently
reported adverse events, but was similar across treatment
groups (18–20%). Investigator-assessed drug-related adverse
events occurred in 9% of patients. Drug-related adverse
events that occurred in more than one patient in a
treatment group were oral candidiasis, dysphonia, phar-
yngolaryngeal pain, insomnia, palpitations, and headache.
The incidence of asthma exacerbations reported during
treatment was 15% in the FSCBHR group, 21% in the FPBHR
group, and 24% in the FPREF group. An ad-hoc analysis
showed no statistically signiﬁcant differences between any
pair of treatments or across all treatments (p ¼ 0.056).
Discussion
To our knowledge, this is the ﬁrst study to examine
the effect of reducing BHR and controlling clinical
asthma symptoms with either an ICS alone or adding a LABAto an ICS while titrating treatment using two different
strategies, one based solely on clinical parameters
(reference strategy) and the other based on clinical
parameters plus optimizing control of BHR (BHR strategy).
This study shows that asthma control using titration of
clinical parameters alone or clinical parameters plus BHR is
achieved at low doses of FP. The results also indicate that
improvements in BHR and clinical measures of asthma
control are achieved at even lower doses of FP when
administered with salmeterol in the same device (FSC)
compared with ICS alone, although these ﬁndings did not
reach statistical signiﬁcance.
Our results are qualitatively similar to the ﬁndings of Sont
et al., a study that guided the design of the present study.17
In their 2-year study, higher doses of either budesonide
(BUD) or beclomethasone dipropionate (BDP) were required
to optimize control of both BHR and clinical parameters,
while lower doses of BUD or BDP adequately controlled
clinical parameters, but not BHR. Similar ﬁndings have been
reported with other biomarkers used to titrate asthma
treatment.15,24,25 For example, Green et al. used induced
sputum eosinophil count rather than BHR to guide treatment
titration, and reported a dose effect of ICS (with BDP,
budesonide [BUD], or FP) in order to achieve control of
sputum eosinophils.15
The studies reported by Sont and Green allowed for
continuation of the speciﬁc baseline ICS, which consisted
primarily of BDP, BUD, and FP. The present study standar-
dized the treatment ICS, utilizing only FP, and recent studies
have shown that maximal improvements in lung function and
BHR can often be achieved with a dose of FP in the range of
200mcg per day.18,26 By contrast, higher doses of BDP and
BUD are required to achieve a similar therapeutic response
in lung function and BHR.18 This may in part explain the
relatively limited ICS dose response for these outcomes
observed in the present study compared with those of Sont
and Green.
The clinical beneﬁts of salmeterol and concurrent ICS
treatment have been repeatedly demonstrated.7,27 For
example, for patients symptomatic on low-dose ICS, adding
salmeterol compared with increasing the dose of ICS has
been shown to improve lung function, decrease symptoms
and rescue albuterol use, improve BHR, and control both
tissue and sputum markers of inﬂammation.3,4,6,7,9,28,29
Additionally, in patients requiring medium doses of ICS for
asthma stability, the addition of salmeterol allows a
reduction in the dose of ICS without any loss of clinical
asthma control parameters and without any increase in
biopsy and bronchoalveolar lavage (BAL) markers of airway
inﬂammation.30–32
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Table 5 Treatment changes triggered by BHR alone.
BHR+clinical
markers (%)
Clinical markers
alone (%)
FPBHR 43 57
FSCBHR 40 60
BHR plus clinical measures in determining asthma therapy 671It is also important to note that in the present study,
although not designed to compare rates of exacerbation, a
lower number of exacerbations occurred when salmeterol
was added to FP relative to FP alone, regardless of
treatment strategy. The highest incidence of exacerbations
was seen in the FPREF group followed by the FPBHR group. The
lowest incidence of exacerbations was seen in patients
receiving both FP and salmeterol in the same device (FSC),
for whom both clinical parameters and control of BHR were
a target of the treatment strategy (FSCBHR group). Thus,
treatment with FSC to control BHR and symptoms reduced
the incidence of exacerbations by 9 and 6 percentage points
when compared with FP for patients treated using the
clinical (FPREF group) or BHR (FPBHR group) strategies,
respectively.
Another important design consideration in interpreting
the results of this study is that the present study employed a
ﬂexible dosing scheme, whereas other studies comparing
FSC and FP did not allow dose reduction once control was
achieved33 and others used a constant dosing scheme
comparing FSC with adjustable dosing of budesonide/
formoterol.34 Although these studies differed in design and
baseline characteristics of the study populations, the
incidence of exacerbations in the studies reported by
Bateman et al. and FitzGerald et al.33,34 were lower than
in the present study, suggesting that constant dosing over
time provides better control of exacerbations. This supposi-
tion is also supported by studies that show a loss of asthma
control when ICS are withdrawn35 or tapered too ra-
pidly.36,37
There are potential limitations of the present study. First,
the schedule for dose alterations was every 8 weeks.
Guidelines1,38 suggest that once asthma control is achieved,
treatment doses should not be altered for at least 12 weeks,
although few studies have examined this directly. However,
some studies have shown that maximal or near maximal ICS
effects are achieved after 8 weeks.18 Nonetheless, the fact
that patients often lost control in the 8-week period
following the downward titration in dose suggests that the
ﬂexible dosing strategy used in this study would not be
optimal in clinical practice and that a strategy of longer
term maintenance of control is appropriate. Second,
methacholine challenge is one of several methods for
assessing underlying airway inﬂammation; however, it may
not deﬁne the inﬂammatory phenotype for all patients. As
shown by Van Den Berge et al.,39 changes in PC20 methacho-
line are related to changes in airway inﬂammation and
caliber and was, therefore, felt to be appropriate for use in
this study. In addition, in the study by Sont et al.,13 study
visits were every 12 weeks, whereas, in the current study,
study visits were every 8 weeks. Although unlikely (because
dose response to ICS is maximal in days, not weeks), the
more frequent visits in the current study could have impacted
the results compared with the study by Sont et al.13
To assess the use of methacholine responsiveness as a
biomarker in determining treatment strategy (a measure
that most clinicians do not have the opportunity to
evaluate), we retrospectively examined whether BHR was
an independent factor in driving dose changes when clinical
parameters alone would not have resulted in a dose
alteration. Notwithstanding the fact that we found a slightly
higher dose of ICS was required in the BHR groups, only 9% ofvisits required an increased dose of ICS due to uncontrolled
BHR that otherwise would not have been triggered by
observation of clinical parameters alone (Table 5). The study
suggests that clinicians can be conﬁdent that the assessment
of clinical measures can predict the need for additional
therapy in most patients. As discussed above, the fact that
patients often lost control in the 8-week period following
the downward titration in dose suggests that the dosing
strategy used in this study would not be optimal in clinical
practice and that a strategy of longer term maintenance of
control is appropriate.
With respect to pharmacotherapy, the current study
supports that control of clinical markers and BHR can be
achieved at a lower dose of ICS when used concurrently with
salmeterol. In addition, this study suggests that the clinician
can have conﬁdence that BHR is controlled in most patients
by monitoring clinical symptoms when using FSC. Finally,
although it has been shown that asthma treatment directed
at maintaining a high level of clinical asthma control is an
effective strategy,32 the current study suggests that fre-
quent dose alterations may lead to uncontrolled asthma.Conﬂict of interest statements
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